Asahi Kasei Life Science has licensed Noguchi Institute's precision ADC technology. The novel ADC modality enables precise DAR and attachment-site control for single- and dual-payload ADCs, improving predictability of efficacy and safety. The technology will be commercialized and co-developed.
Insights / Technology
TechnologyAsahi Kasei Life Science licenses Noguchi Institute precision ADC technology
Asahi Kasei Life Science has licensed Noguchi Institute's precision antibody-drug conjugate technology, which enables precise drug-to-antibody ratio and attachment-site control for single- and dual-payload ADCs, improving predictability of efficacy and safety.
